ArticleFrontiers in oncology2025
Study on the application of modified negative pressure wound therapy with instillation in cervical anastomotic leakage after oesophageal cancer surgery.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This study aims to explore the feasibility and safety of modified negative-pressure wound therapy with instillation (NPWTi) for the treatment of cervical anastomotic leakage (CAL) after oesophageal cancer surgery. Methods: A retrospective analysis was conducted on 17 patients who developed CAL after oesophageal cancer surgery and received modified NPWTi treatment at our hospital from 2021 to 2024. The primary outcome was the time to healing, defined as the number of days from the initiation of modified NPWTi to complete fistula closure. Secondary outcomes included wound odour improvement and patient comfort. Results: A total of 17 patient were collected, including 10 men and seven women, with an average age of 73.71 ± 8.01 years. None received neoadjuvant therapy, and no patients had diabetes; preoperative albumin was 38.77 ± 3.58 g/L. The occurrence of CAL was noted at 8.88 ± 3.15 d (95% CI: 7.26 to 10.51 d) post-surgery. The modified treatment was commenced 0-12 d after CAL diagnosis, with the earliest case starting on the day of diagnosis. The mean duration of modified NPWTi was 10.88 ± 6.54 d (95% CI: 7.52 to 14.25 d). For the primary outcome, the time from treatment initiation to complete healing was 15.00 ± 7.26 d (95% CI: 11.27 to 18.73 d), with a minimum of five days. No mediastinal or pleural infections related to NPWTi occurred during the treatment. For the secondary outcomes, a significant improvement in wound odour was observed following the administration of the modified NPWTi (P<0.001), with an improvement rate of 100% (95% CI: 85-100%). During the treatment, the patients reported feeling comfortable and expressed overall satisfaction. Conclusion: Modified NPWTi demonstrated significant efficacy and convenience in treating CAL after oesophageal cancer surgery, benefiting both patients and healthcare providers with good safety profiles, thus warranting broader clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.